Prof. Matthias Tschöp, Prof. Svetlana Mojsov, Prof. Richard DiMarchi receive Broermann Medical Innovation Award

From Lab to Therapy: Broermann Award Recognizes Obesity and Diabetes Research at Helmholtz Munich

Awards & Grants

Prof. Matthias Tschöp, former CEO and Scientific Director of Helmholtz Munich and founding director of the Institute for Diabetes and Obesity, will receive the Broermann Medical Innovation Award 2026. The award recognizes his research at Helmholtz Munich, which has significantly changed the treatment of obesity and type 2 diabetes. Yet this scientific journey is far from over: Research into new therapeutic approaches continues at Helmholtz Munich.

See more from Helmholtz Munich on Google. Activate

The Foundation: Understanding Metabolism to Develop New Therapies

Hunger, satiety, blood glucose, and body weight are not controlled by a single hormone. Different signals from the gut, adipose tissue, liver, and pancreas continuously provide the brain with information about the body’s metabolic state. This insight led to a new therapeutic approach: drugs that mimic several metabolic signals at the same time. These so-called polyagonists activate multiple receptors and can thereby influence blood glucose regulation, appetite, and body weight simultaneously.  

 

Several scientific contributions paved the way for this approach and for modern treatments for obesity and type 2 diabetes:  

Prof. Svetlana Mojsov identified the sequence of the biologically active form of GLP-1, making a major contribution to the discovery of GLP-1 as an incretin. GLP-1 is a gut hormone that regulates insulin secretion after food intake. Matthias Tschöp and Prof. Richard DiMarchi (Indiana University Bloomington), in turn, developed drugs that target multiple hormone receptors simultaneously.

 

The award-winning research represents a key milestone in a scientific journey that continues to shape new therapeutic approaches for obesity and type 2 diabetes.  

 

The Future: Making Metabolic Therapies More Precise

Building on the development of polyagonists, current research at Helmholtz Munich is taking this concept one step further. Researchers are exploring hybrid drugs that act on several metabolic pathways at once. They can also carry additional therapeutic components directly to the cells where they are needed. This could make future treatments for obesity and diabetes more targeted. So far, the approach has been studied in mice, and further research is needed to determine whether it can also work in humans

 

Broermann Award Recognizes a New Therapeutic Principle

The Broermann Medical Innovation Award comes with prize money of one million euros and annually recognizes scientific achievements that advance medical innovation and contribute to improving patient care. Candidates undergo an international review process.

In 2026, the award goes to the research trio Svetlana Mojsov of Rockefeller University, Richard DiMarchi of Indiana University, and Matthias Tschöp, now President of LMU Munich. The award thus brings together different contributions to the development of modern metabolic therapies: research on biologically active GLP-1, the development of hormone-based drugs, and the concept of therapeutically combining multiple metabolic signals in a single molecule.

Related news

Portrait Matthias Tschöp

Diabetes,

Reversing Obesity with Multi-Receptor Drugs

Prof. Matthias Tschöp explains why multi-receptor drugs are game changers in treating obesity and preventing diabetes effectively and safely – and why they are not a “miracle treatment” for a dream body. This year, he received the Banting Medal for…

Read more